Trials / Completed
CompletedNCT00877760
Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B
Augmenting Response to Entecavir Using a Temporary Peginterferon Alpha-2a add-on Strategy for the Treatment of HBeAg-positive Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 184 (actual)
- Sponsor
- Foundation for Liver Research · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate whether it is possible to augment the response of patients with HBeAg-positive chronic hepatitis B to entecavir by using a temporary peginterferon alpha-2a add-on strategy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegylated interferon a-2a | 180 μg, once per week s.c. for 24 weeks |
| DRUG | Entecavir | 0.5 mg once daily per os, either 72 weeks or 96 weeks |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2009-04-08
- Last updated
- 2014-03-28
Locations
13 sites across 5 countries: China, Netherlands, Poland, Romania, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00877760. Inclusion in this directory is not an endorsement.